Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)

Next Previous
X
Search
Trial Profile

A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Capecitabine (Primary) ; Capivasertib (Primary) ; Durvalumab (Primary) ; Fulvestrant (Primary) ; Paclitaxel (Primary) ; Trastuzumab-deruxtecan (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Acronyms DB-08; DESTINY-Breast08
  • Sponsors AstraZeneca

    • Most Recent Events

    • 02 Dec 2024 According to Daiichi Sankyo media release, data from this trial will be presented in a poster presentation, on December 12 2024, 12:30 - 2:00 pm at San Antonio Breast Cancer Symposium (#SABCS24).
    • 01 Dec 2023 According to Daiichi Sankyo Company Media Release, results from this study will be presented at the San Antonio Breast Cancer Symposium, 2023.
    • 20 Jun 2023 Planned End Date changed from 10 Aug 2023 to 28 Nov 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top